National Jewish Health clinical trials
Listed in the registry as: University, hospital or other organization.
The registry lists 109 studies whose lead sponsor is National Jewish Health. 14 are recruiting or about to start. Per ClinicalTrials.gov, last updated Aug 28, 2026.
Keep track of what changes. Save the National Jewish Health studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesStatus
Focus areas
Conditions National Jewish Health leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.
Studies
Recruiting first, then most recently updated. Showing 50 of 109. Browse all 109 →
- Deployment-Related Lung Disease Research Database and BiorepositoryRecruitingNCT03035097
- Enhancing Hypnotic Medication Discontinuation in Primary CareRecruitingNCT06435520Phase 4
- MOBoxy: MoblO2 to Maintain OxygenationNot yet recruitingNCT07222592Not applicable
- Mycobacteriophage Treatment of Non-tuberculosis MycobacteriaEnrolling by invitationNCT06262282
- Alveolar Macrophage Programming Following Endotoxin ExposureRecruitingNCT03859050Not applicable
- Effect of Omalizumab in the Skin of Food Allergy PatientsRecruitingNCT06618963Phase 4
- The Role of Laryngopharyngeal Reflux in IPFRecruitingNCT03418350
- PATIENCE Trial: Prospective Algorithm for Treatment of NTM in Cystic FibrosisEnrolling by invitationNCT02419989
- PREDICT Trial: PRospective Evaluation of NTM Disease In CysTic FibrosisEnrolling by invitationNCT02073409
- Nasal Inflammation Following Endotoxin Challenge in Patients With AsthmaNot yet recruitingNCT06270576Phase 1
- Simultaneous quanTification of Elexacaftor/tezAcaftor/Ivacaftor Via Reverse Phase High Performance liquiD chromatographYEnrolling by invitationNCT05822102
- Lung Clearance Index to Identify Scleroderma Patients at Risk for ILDRecruitingNCT04535245
- Role of Genetics in Idiopathic Pulmonary Fibrosis (IPF)RecruitingNCT01088217
- Epigenetic Regulation of Altered T-cell Immunity in SarcoidosisRecruitingNCT03145922
- Sildenafil Exercise: Role of PDE5 InhibitionCompletedNCT04039087Phase 2/3
- Sub-Sensitivity to Long-Acting Bronchodilators (LABA)CompletedNCT01117116Not applicable
- Identification of Pathways to Mitigate Immune-Related Adverse Events With Cancer ImmunotherapyCompletedNCT04283539
- Safety and Efficacy of Sildenafil in Cystic Fibrosis (CF) Lung DiseaseCompletedNCT00659529Phase 1/2
- IV Colistin for Pulmonary Exacerbations: Improving Safety and EfficacyCompletedNCT02918409Phase 4
- Use of DNAse in Neutrophilic AsthmaCompletedNCT03994380Phase 1/2
- COVID-19 Vaccine Response in Chronic Respiratory ConditionsCompletedNCT05313087
- Glycerol Phenylbutyrate Corrector Therapy For CF (Cystic Fibrosis)TerminatedNCT02323100Phase 1/2
- Utility of Lung Clearance Index Score as a Noninvasive Marker of Small Airways DiseaseActive, not recruitingNCT03241420
- Observational Trial of the Longitudinal Effects of CFTR Modulator DrugsCompletedNCT04353752
- Bacterial Gene Profiling to Predict Antibiotic Resistance During Cystic Fibrosis Pulmonary ExacerbationsCompletedNCT04341532
- Host and Bacterial Mechanisms During Cystic Fibrosis Pulmonary ExacerbationsCompletedNCT04354038
- A Prognostic Transcriptomic Signature for Chronic Hypersensitivity PneumonitisActive, not recruitingNCT04844359
- Epigenetic Regulation of Immunity in Alpha-1 Anti-trypsin DeficiencyCompletedNCT02691611
- Use of Blinded Tapering for Hypnotic DiscontinuationActive, not recruitingNCT04050176Phase 3
- An Asthma Collaboration to Reduce Childhood Asthma Disparities on the Navajo NationActive, not recruitingNCT03377647Not applicable
- Therapist-Directed VS Online Therapy for Insomnia Co-Occuring with Sleep ApneaActive, not recruitingNCT03109210Not applicable
- Saracatinib in the Treatment of Idiopathic Pulmonary FibrosisActive, not recruitingNCT04598919Phase 1/2
- Telecommunication Enhanced Asthma ManagementCompletedNCT00958932Not applicable
- Reverse HFpEF: Ketogenic Reversal of Heart Failure With Preserved Ejection Fraction StudyCompletedNCT04942548Not applicable
- : TRANSITION: An Observational Study of Transition From Lumacaftor/Ivacaftor to Tezacaftor/Ivacaftor (Tez/Iva)CompletedNCT03445793
- Healthcare-associated Links in Transmission of Nontuberculous Mycobacteria in Cystic FibrosisCompletedNCT04024423
- The Breathe Well Program for Adults With AsthmaCompletedNCT02761837Not applicable
- Changing School Start Times: Impact on Student, Family, Teacher, and Community HealthCompletedNCT03964181
- T Cell Memory Fuels the Innate Response in Chronic CF Lung DiseaseCompletedNCT04397861
- Phase II Study of Digitoxin to Treat Cystic FibrosisCompletedNCT00782288Phase 2
- The Role of Bacterial Toxins in Human Skin DiseaseStatus unknownNCT02910791
- Utility of CD64 and TLR2 Assays to Diagnose Acute Pulmonary Exacerbations in Cystic FibrosisCompletedNCT04397809
- Genetics and Genomics of Aspirin Exacerbated Respiratory Disease (AERD)SuspendedNCT04261582
- Tailored Treatment to Enhance Risk Perception in Sleep ApneaCompletedNCT02314858Not applicable
- Creation of Home-based Asthma Real-World Measures With Mobile Health StudyStatus unknownNCT04462224
- Measuring Omalizumab Responses Using Real-world Evidence (MORRE) StudyStatus unknownNCT04724278
- Exposure in Epigenetic Regulation of Immune Response in Chronic Beryllium Disease (CBD)CompletedNCT02604693
- Clinical Outcomes of Triple Combination Therapy in Severe Cystic Fibrosis Disease.CompletedNCT04038710
- Benralizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) StudyStatus unknownNCT03010436Phase 2
- Impact of Increased Immunoglobulin E to Anti-herpes Simplex Virus -1 Innate Immune Responses in Atopic Dermatitis Patients With Eczema HerpeticumStatus unknownNCT04060550